Browse Studies — Arctuva

A Non-interventional, Prospective, Multi-country Study Collecting Real-world Data on the Characteristics, Treatment Patterns, and Outcomes of Patients With Transthyretin (ATTR) Amyloidosis

The MaesTTRo study aims to enroll a global cohort of patients with transthyretin (ATTR) amyloidosis to longitudinally observe the natural course of the disease…

Transthyretin AmyloidosisATTR-CMATTRv-PN+3 more

Estimated

~$10 – $1,125

AstraZenecaNCT06465810

Phase 3

An Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of ALXN2220 in Adult Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

The purpose of Study ALXN2220-ATTRCM-302 is to evaluate the long-term safety, tolerability and efficacy of ALXN2220 in adult participants with ATTR-CM treated …

Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Estimated

~$10 – $8,750

Alexion Pharmaceuticals, Inc.NCT07789483

Phase 4

An Open-Label Study to Investigate the Long-Term Effects of Acoramidis on Cardiac Function, Structure and Cardiac Amyloid Burden in Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

The study aims to evaluate the effect of acoramidis on cardiac functional and structural improvement in participants with ATTR-CM.

Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)AmyloidosisAmyloid Cardiomyopathy+1 more

Estimated

~$10 – $8,750

Eidos Therapeutics, a BridgeBio companyNCT07695701

Myocardial & Hepatic Shear Wave Velocity Measurements in Patients With Non-Reduced-Ejection Fraction Heart Failure and Control Subjects - US Benchmarking Clinical Study

The goal of this observational study is to measure shear wave velocity (SWV) in patients with non-reduced left ventricular ejection fraction (LVEF) heart failu…

HFpEF - Heart Failure With Preserved Ejection FractionHFmrEFATTR-CM (Transthyretin Amyloid Cardiomyopathy)+2 more

Estimated

~$10 – $1,125

eMyosound SASNCT07215715